NCT00743353已完成早期 1 期
An Exploratory, Multi-Center, Open Label, Non-Randomized Study of F-18 RGD-K5
Siemens Molecular Imaging1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5
研究概览
简要总结
The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "[F-18] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic tumor. the system.
详细描述
[F-18]RGD-K5 is being investigated as a diagnostic radiopharmaceutical for the detection and localization of angiogenesis tissue or lesions supporting the application and role of integrins in anti-angiogenic therapies to benefit patients with cancer and inflammatory diseases.
The primary objectives of this exploratory study are:
- To gain information on biodistribution of [F-18]RGD-K5, and to evaluate the PET images with [F-18]RGD-K5 for resolution, signal to background ratio and for the detection and localization of angiogenesis tissue. This Exploratory Investigational New Drug (EIND) study is designed to obtain preliminary imaging and fundamental biodistribution, metabolism and safety information to demonstrate early proof of concept. The information collected under this study will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management for the subject.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Days 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For Normal Volunteers
- •Subject is ≥ 18 years old at the time of investigational product administration (Subject is male or female of any race / ethnicity)
- •Subject or subject's legally acceptable representative provides informed consent
- •Subject is capable of complying with study procedures
- •Subject is capable of communicating with study personnel
- •For Cancer Subjects (same first four bullets as 'normals')
- •Subject must have had a diagnostic imaging study and is suspected of having a primary or metastatic tumor(s) ( > 2 cm, except breast tumor)-sarcoma; melanoma; lung cancer [including small cell and non-small cell lung cancer (NSCL)]; high grade glioma (including glioblastoma multi-forms), anaplastic astrocytoma, and anaplastic oligodendroglioma; breast carcinomas, and head and neck tumors, including laryngeal squamous cell carcinoma
- •Subject is scheduled to have a clinical [F-18]FDG PET scan within ± 7 days (with no interventions between the two PET scans) of the investigational, [F-18]RGD-K5 PET scan
- •Subject is scheduled to undergo resection or biopsy of the target tumor as a result of routine clinical treatment
- •Subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET/CT imaging
- •Subject has laboratory test results within the following ranges:
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limits of normal
- •Serum creatinine ≤ 1.5 institutional upper limits of normal
- •Platelet count of > 75,000x106/L
- •Hemoglobin value of > 9 g/dL
- •ANC > 1.2 x 106 /mL
- •Exclusion Criteria 'Normals':
- •Subject is < 18 at the time of investigational product administration
- •Female subject is pregnant or nursing:
- •by testing on site at the institution (serum or urine ßHCG) within 24 hours prior to the investigational product administration
- •Subject is unable to remain still for duration of imaging procedure
- •Subject has a history of renal disease
- •Subject has previously received [F-18]RGD-K5 at any time, or any other investigational product in the past 30 days or will receive any other investigational product within 48 hours after the [F-18]RGD-K5 injection
- •Subject has not been involved in an investigative, radioactive research procedure or therapeutic procedure within the past 6 months
- •Subject has any other condition or personal circumstance including severe claustrophobia, severe dyspnea, severe back pain etc, that, in the judgment of the investigator, might interfere with the collection of complete good quality data
- •Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.
- •For Cancer Subjects (first three bullets the same as 'normals')
- •Subject is < 18 at the time of investigational product administration
- •Female subject is pregnant or nursing:
- •by testing on site at the institution (serum or urine ßHCG)
- •Subject is unable to remain still for duration of imaging procedure
- •Subject has known hyper or hypo-coagulation syndromes. (e.g., Protein C, S deficiency, Hemophilia A/B/C, Factor-V Leiden, etc.)
- •Subject has previously received [F-18]RGD-K5 at any time, or any other investigational product in the past 30 days or will receive any other investigational product within 48 hours after the [F-18]RGD-K5 injection.
- •Subject has inadequate tumor size (< 2 cm , except for breast tumor) or volume to allow for biopsy
- •Subject has any other condition or personal circumstance including severe claustrophobia, severe dyspnea, severe back pain etc, that, in the judgment of the investigator, might interfere with the collection of complete good quality data
- •Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.
排除标准
- 未提供
研究组 & 干预措施
A
Experimental
16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
干预措施: F-18 RGD-K5 (Drug)
结局指标
主要结局
To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5
时间窗: imaging study-participation only days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human BodySolid Tumors Harboring NTRK FusionNCT04275960Bayer24
Unknown
不适用
Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection FractionFerric CarboxymaltoseHeart Failure With Reduced Ejection FractionArrhythmias, CardiacNCT04974021Aristotle University Of Thessaloniki106
已完成
1 期
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL CCarcinoma, Non-Small-Cell LungNCT03623750Instituto Oncológico Dr Rosell23
已完成
早期 1 期
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037Head and Neck CancerHepatic CarcinomaLung CancerRenal Cell CarcinomaSquamous Cell CarcinomaNCT00884520Siemens Molecular Imaging16
终止
1 期
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)Advanced Hepatocellular CarcinomaNCT01942083Korea Otsuka Pharmaceutical Co., Ltd.33